An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quanterix Corporation (NASDAQ: QTRX) released a statement addressing media reports concerning its engagement with Cassava Sciences. The company clarified that it performed sample testing using blinded samples from Cassava but did not interpret the results or prepare the accompanying data presented at the Alzheimer’s Association International Conference (AAIC) in July 2021. Quanterix's Simoa technology is trusted by major pharmaceutical companies and is extensively used in research across various diseases, including Alzheimer’s. The company is committed to advancing precision health through innovative biomarker analysis.
Positive
Simoa technology trusted by 24 of the top 25 pharmaceutical companies.
Technology featured in over 1,300 research papers and presentations globally.
Focus on advancing precision health and improving disease detection and treatment.
Negative
None.
BILLERICA, Mass.--(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today released the following statement in response to news reports related to Cassava Sciences.
Cassava previously engaged Quanterix’ Accelerator laboratory to perform sample testing based on blinded samples provided by Cassava. Quanterix or its employees did not interpret the test results or prepare the data charts presented by Cassava at the Alzheimer’s Association International Conference (AAIC) in July 2021 or otherwise.
Quanterix is widely recognized for its commitment to business integrity and to upholding the highest standards of quality. Quanterix’ Simoa technology provides exquisite sensitivity for detecting and measuring biomarkers across a wide range of disease states, including neurology, oncology, and infectious disease. The Simoa technology has been trusted by 24 of the top 25 top pharmaceutical companies, and Quanterix customers have described the use of Simoa technology in over 1,300 research papers and presentations worldwide.
Quanterix harnesses the power of biomarkers with the latest detection solutions to enable a precision health vision of proactive, preventative healthcare and believes that, in doing so, can change the course of how diseases like Alzheimer’s are currently studied and treated.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
What is the recent press release about Quanterix Corporation (QTRX)?
The press release clarifies Quanterix's role in sample testing for Cassava Sciences, emphasizing that it did not interpret the results or prepare data for the Alzheimer's Association Conference.
How does Quanterix's Simoa technology impact healthcare?
Simoa technology is designed to improve disease detection, enable earlier interventions, and enhance treatment methods across various disease states.
What recognition does Quanterix Corporation receive in the pharmaceutical industry?
Quanterix is recognized for its Simoa technology, which is trusted by 24 of the top 25 pharmaceutical companies for biomarker analysis.
When was the press release regarding Quanterix Corporation (QTRX) issued?
